Abivax S.A. (ABVX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ABVX
- Company Abivax S.A.
- Price $101.2
- Changes Percentage 12.25
- Change 11.045
- Day Low $92.66
- Day High $101.2
- Year High $148.83
- Year Low $5.69
- Market Cap $5,910,946,275
- Price Avg 50 EMA (D) $117.5
- Price Avg 200 EMA (D) $109.59
- Exchange NASDAQ
- Volume 7,147,928
- Average Volume 1,357,980
- Open $93.37
- Previous Close $90.15
- EPS -5.37
- PE -16.79
- Earnings Announcement 2026-09-14 04:00:00
- Shares Outstanding $65,567,901
Company brief: ABIVAX S.A. (ABVX )
- Healthcare
- Biotechnology
- Mr. Marc M. P. de Garidel M.B.A.
- https://www.abivax.com
- US
- N/A
- 10-20-2023
- US00370M1036
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.